RSCM
VERV

Rock Springs Capital Management’s Verve Therapeutics VERV Stock Holding History

Rock Springs Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-558,837
Closed -$8.06M – 125
2023
Q1 		$8.06M Hold
558,837
– – 0.19% 79
2022
Q4 		$10.8M Hold
558,837
– – 0.26% 70
2022
Q3 		$19.2M Buy
558,837
+54,800
+11% +$1.75M 0.5% 55
2022
Q2 		$7.7M Hold
504,037
– – 0.22% 87
2022
Q1 		$11.5M Sell
504,037
-398,889
-44% -$11.4M 0.29% 77
2021
Q4 		$33.3M Sell
902,926
-59,900
-6% -$2.52M 0.77% 43
2021
Q3 		$45.3M Hold
962,826
– – 0.95% 37
2021
Q2 		$58M Buy
+962,826
New +$40M 1.15% 27

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Rock Springs Capital Management's VERV Position: Q2 2023 in Review

Rock Springs Capital Management sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 558,837 shares — an estimated $8.06M sold.

Rock Springs Capital Management first reported a position in VERV in Q2 2021 and held it in 8 quarters. The position peaked at $58M in Q2 2021. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Rock Springs Capital Management reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Rock Springs Capital Management sold 558,837 Verve Therapeutics shares in Q2 2023, an estimated $8.06M.
  • Rock Springs Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 8 quarters.
  • Rock Springs Capital Management's Verve Therapeutics position peaked at $58M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.